MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
Mammotome, a breast cancer treatment company, has launched the Mammotome Prime MR system, described as the first in-room MR vacuum-assisted breast biopsy system, designed to allow clinicians to perform MRI-guided biopsies within the MRI suite. The system enables tissue sampling without requiring patients to be moved to a separate procedure area, aiming to streamline workflow and reduce procedure time. The Mammotome Prime MR system enables a stronger vacuum with larger tissue samples and an 8-gauge needle.
More
Posted by MedCloudInsider Editors on 02/24/20260 comments
Researchers at the University of Missouri are developing methods to make AI-driven scientific predictions more trustworthy by improving model transparency and reliability. The team is focused on strengthening confidence in machine learning systems used to analyze complex scientific data, particularly in areas where inaccurate predictions could have significant downstream consequences. The database, called PSBench includes 1.4 million annotated protein structure models that give scientists reliable information needed to build AI systems to assess the quality of protein structure models. Previous tools lack the information required to accurately predict every type of protein, but PSBench provides a solution to this marking a significant step in applying protein models to develop treatments.
More
Posted by MedCloudInsider Editors on 02/20/20260 comments
Metabolon, a global leader in metabolomics, announced that its metabolomics platform enabled what the company describes as the largest metabolomic analysis to date in CAR-T cell therapy, generating new insights into severe neurotoxicity associated with the treatment. The study analyzed metabolic profiles from patients undergoing CAR-T therapy and identified distinct metabolite patterns correlated with immune effector cell-associated neurotoxicity syndrome (ICANS), a potentially life-threatening complication. Researchers were able to identify clear, reproducible metabolic signatures that classified patients who developed high-grade NEs using metabolomics to reveal mechanisms that are invisible to genomic, proteomic and cellular assays.
More
Posted by MedCloudInsider Editors on 02/18/20260 comments
Unchained Labs, a life sciences research company, has launched Stuntman, a new AI-driven automation platform designed to help life sciences teams accelerate experimental workflows and reduce reliance on manual laboratory processes. Stuntman combines artificial intelligence, robotics and software orchestration to automate complex, multi-step experiments, allowing scientists to focus more on analysis and discovery rather than routine execution. The integration allows scientists to describe what they aim to do in natural language and have these prompts turn into workflows, help plan experiments, interpret results and guide automation.
More
Posted by MedCloudInsider Editors on 02/09/20260 comments
MetaVia, a clinical-stage biotechnology company specializing in cardiometabolic diseases, has reported positive results from AI-based modeling conducted as part of its ongoing collaboration with Syntekabio, confirming key therapeutic targets for vanoglipel. The modeling work validated the biological mechanisms underlying the drug candidate, strengthening confidence in its development strategy and supporting continued clinical and preclinical efforts. MetaVia aims to continue leveraging Syntekabio AI to optimize the therapeutic profile of vanoglipel.
More
Posted by MedCloudInsider Editors on 02/09/20260 comments
Takeda, a Japanese pharmaceutical company, has agreed to a deal worth up to $1.7 billion with Iambic Therapeutics to expand its use of artificial intelligence in drug discovery, reinforcing a broader push to modernize early-stage research. Under the agreement, Takeda will use Iambic’s AI-driven platform to design and optimize small-molecule drug candidates, with an initial focus on multiple therapeutic targets. The structure includes upfront payments, research funding, and milestone-based fees tied to development progress. Takeda will also gain access to Iambic's NeuralPLexer model that predicts how drug molecules bind to proteins. The approach to use AI predictions fast-tracks discovery and reduces timelines, saving months of traditional lab work and creating something that could not have been done before.
More
Posted by MedCloudInsider Editors on 02/09/20260 comments
Brainomix, a global leader in AI-powered imaging, has launched a next-generation stroke AI platform called Brainomix 360 Next Generation featuring novel net water uptake technology, unveiling the system at the International Stroke Conference (ISC). The platform is designed to enhance clinicians' assessment of ischemic stroke by providing more detailed insights into brain tissue damage and edema through advanced imaging analysis. The technology helps clinicians more accurately assess tissue viability and treatment options, particularly in time-critical stroke cases.
More
Posted by MedCloudInsider Editors on 02/03/20260 comments
Reprocell, an integrated stem cell and gene-editing service provider, has launched StemEdit, a new clinical gene-editing system licensed from Profulent, called OpenCRISPR-1™. The service is intended to support pharmaceutical, biotech and academic researchers developing cell and gene therapies by providing edited iPSC lines suitable for preclinical and clinical applications. StemEdit is designed to improve precision, reproducibility and turnaround time compared with traditional gene-editing workflows.
More
Posted by MedCloudInsider Editors on 02/03/20260 comments
Renew Biotechnologies, a nucleic-acid-based clinical development company, has advanced its epigenetic diagnostics portfolio with the launch of Path Fertility’s NOA Guide, a tool designed to support clinical decision-making for men with non-obstructive azoospermia (NOA). The diagnostic applies epigenetic analysis to assess testicular tissue and help clinicians determine the likelihood of sperm retrieval, informing treatment planning and patient counseling. The guide is intended to provide more objective insight than conventional assessments, which often rely on limited biomarkers or invasive procedures. The collaboration advances clinical applications that helps partners deliver emerging biological insights into clinically deployable diagnostics.
More
Posted by MedCloudInsider Editors on 02/03/20260 comments
A new survey from Kipu Health, a leader in behavioral health technology, finds that artificial intelligence is rapidly becoming a clinical and workforce imperative in behavioral health. The research shows growing adoption of AI tools to support documentation, care coordination and operational efficiency, as providers contend with rising demand for services and persistent staffing shortages. Respondents indicated that AI is increasingly seen not as an experimental technology, but as a necessary component of delivering sustainable, high-quality behavioral health care.
More
Posted by MedCloudInsider Editors on 01/27/20260 comments
Lunai Bioworks, an AI-powered drug discovery and biodefense company, has expanded its NIH-funded artificial intelligence research program into a commercial drug discovery effort focused on alcohol use disorder (AUD). The company is applying its AI-enabled platform, which models neural circuits and behavior, to identify and validate new therapeutic candidates targeting the underlying biology of addiction. The expansion marks a transition from government-backed research into a commercially driven development program toward candidate nomination and downstream development.
More
Posted by MedCloudInsider Editors on 01/27/20260 comments
AIDS Healthcare Foundation (AHF) has modernized its contract management processes using CloudMoyo’s generative AI-powered IntelliDoc Analyze (CDA) platform. CloudMoyo is a global AI-first consulting solutions firm. The platform is designed to improve efficiency and accelerate document analysis and data extraction. The solution uses AI to analyze contracts, extract key terms, identify obligations and flag potential issues, helping AHF manage agreements more consistently as it operates across multiple regions and regulatory environments. The platform enables faster review cycles while improving visibility into contractual commitments.
More
Posted by MedCloudInsider Editors on 01/20/20260 comments